Hepatitis Testing Market – Emerging Trends & Global Future Forecasts

According to the new market research report, “Hepatitis Testing Market by Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), Technology (ELISA, RDT, PCR, INAAT), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Region – Global Forecast to 2026”, The global hepatitis testing market is projected to reach USD 3.6 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 4.7% during the forecast period.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139802887

Global Industry Growth Boosting Factors:

The growth of the global hepatitis testing market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis.

Overview:

This study involved four major activities in estimating the current size of the hepatitis testing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

DRIVER: High burden of hepatitis

Hepatitis is a major public health concern with a high prevalence rate worldwide, despite significant improvements in treatment options, vaccination coverage, and public awareness. Of all the hepatitis types, B and C are the most prevalent and contribute toward higher mortality rates. In 2019, an estimated 296 million and 58 million people were living with chronic HBV and chronic HCV infection, respectively. In underdeveloped countries, the prevalence of hepatitis is high as compared to developed countries

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=139802887

RESTRAINT: Lack of mandates for nucleic acid tests in developing countries

In developing and low-resource countries, NAT is not mandatory due to the expensive nature of this test and the requirement of skilled personnel. In India, by 2016, only 58 out of a total of 2,550 (~2%) blood banks performed NAT for hepatitis diagnosis. In many developing countries such as India and China, ELISA is the only mandatory test, which acts as a major inhibitor for the adoption of NAT. In India, blood screening involves serological testing for hepatitis surface antigens; however, there are no mandates for using NAT. As a result, there is a lack of clarity about results among people undergoing hepatitis diagnostic tests, which acts as a restraint for market growth.

OPPORTUNITY: Growth in biotechnology and biopharmaceutical industries

The demand for immunoassay instruments and consumables is high in the biotechnology and biopharmaceutical industries. As a result, the growth of these industries is expected to support the growth of the hepatitis testing market during the forecast period. In these industries, the growth of the end-user base has compelled many companies to launch new products and invest in developing advanced products. This is considered a positive indicator for market growth as immunoassays are applied at many stages— from product development and manufacturing to quality control—in production.

CHALLENGE: Operational barriers

Clinical laboratories across major markets are still evolving; technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as NGS and lab-on-a-chip PCR devices. Laboratory space also needs to be reconfigured to meet the requirements of conducting specific molecular diagnostic tests used for pathogen detection as a means of avoiding cross-contamination and ensuring efficient time management.

This results in considerable cost escalation to maintain and operate advanced molecular diagnostic instruments, particularly those capable of handling a single sample type. Furthermore, due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the shortage of skilled and technically knowledgeable laboratory technicians to operate advanced hepatitis testing products has hindered their overall adoption, particularly in emerging markets.

Speak to Analyst for More Detailed Information@
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=139802887